Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Calgary, Alberta--(. - September 10, 2026) - Resverlogix Corp. TSX:RVX ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone."One o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.